What now on screening for prostate cancer?

Journal of Medical Screening

Volumn 16, Issue 3, 2009, Pages 109-111

  Law, Malcolm ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CLINICAL STUDY; CLINICAL TRIAL; EDITORIAL; EUROPE; HUMAN; MALE; OUTCOME ASSESSMENT; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; UNITED STATES;

HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349959857     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2009.009067     Document Type: Editorial

References (7)

1. Schröder FH, Hugosson J, Roobol MJ, et al., for the European Randomized Study of Screening for Prostate Cancer (ERSCD) Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328
2. Andriole GL, Crawford ED, Grubb RL, et al., for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319
3. Barry MJ. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009;360:1351-1354
4. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20:680-688
5. Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med 1995;23:1401-1405
6. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2002;92:1582-1592
7. Parkes C, Wald NJ, Murphy P, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 1995;311:340-343